These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26426780)

  • 41. [FUTURE THERAPIES FOR CYSTIC FIBROSIS].
    Fajac I
    Rev Prat; 2015 Oct; 65(8):1106-8. PubMed ID: 26749719
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aquagenic wrinkling of the palms in a patient with cystic fibrosis.
    Grasemann H; Ratjen F; Solomon M
    N Engl J Med; 2013 Dec; 369(24):2362-3. PubMed ID: 24328486
    [No Abstract]   [Full Text] [Related]  

  • 43. Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutation.
    Yousef S; Solomon GM; Brody A; Rowe SM; Colin AA
    Chest; 2015 Mar; 147(3):e79-e82. PubMed ID: 25732475
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CFTR potentiators: not an open and shut case.
    Clancy JP
    Sci Transl Med; 2014 Jul; 6(246):246fs27. PubMed ID: 25101884
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
    Brewington JJ; McPhail GL; Clancy JP
    Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy.
    Virant-Young D; Thomas J; Woiderski S; Powers M; Carlier J; McCarty J; Kupchick T; Larder A
    J Am Osteopath Assoc; 2015 Sep; 115(9):546-55. PubMed ID: 26322933
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Orphan cystic fibrosis drugs find sister diseases.
    Dolgin E
    Nat Med; 2011 Apr; 17(4):397. PubMed ID: 21475214
    [No Abstract]   [Full Text] [Related]  

  • 48. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transformative therapies for rare CFTR missense alleles.
    Oliver KE; Han ST; Sorscher EJ; Cutting GR
    Curr Opin Pharmacol; 2017 Jun; 34():76-82. PubMed ID: 29032041
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T.
    Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF
    J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
    [No Abstract]   [Full Text] [Related]  

  • 52. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
    Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
    Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CT imaging of pediatric patients with cystic fibrosis on ivacaftor therapy.
    Hayes D; Long FR; McCoy KS; Sheikh SI
    Lung; 2014 Oct; 192(5):823-4. PubMed ID: 25099273
    [No Abstract]   [Full Text] [Related]  

  • 54. Update in Cystic Fibrosis 2014.
    Ong T; Ramsey BW
    Am J Respir Crit Care Med; 2015 Sep; 192(6):669-75. PubMed ID: 26371812
    [No Abstract]   [Full Text] [Related]  

  • 55. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience.
    Durmowicz AG; Witzmann KA; Rosebraugh CJ; Chowdhury BA
    Chest; 2013 Jan; 143(1):14-18. PubMed ID: 23276841
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cystic fibrosis, ivacaftor, and the Arg117His-CFTR mutation.
    Accurso FJ
    Lancet Respir Med; 2015 Jul; 3(7):498-9. PubMed ID: 26170070
    [No Abstract]   [Full Text] [Related]  

  • 57. The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review.
    Dryden C; Wilkinson J; Young D; Brooker RJ;
    Arch Dis Child; 2018 Jan; 103(1):68-70. PubMed ID: 27288428
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Promising new era dawns for cystic fibrosis treatment.
    Corbyn Z
    Lancet; 2012 Apr; 379(9825):1475-6. PubMed ID: 22530244
    [No Abstract]   [Full Text] [Related]  

  • 59. Hot off the breath: 'I've a cost for'--the 64 million dollar question.
    Bush A; Simmonds NJ
    Thorax; 2012 May; 67(5):382-4. PubMed ID: 22407889
    [No Abstract]   [Full Text] [Related]  

  • 60. Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry.
    Sawicki GS; Dasenbrook E; Fink AK; Schechter MS
    Ann Am Thorac Soc; 2015 Aug; 12(8):1146-52. PubMed ID: 26073026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.